Ebolavirus: A brief review of novel therapeutic targets

Future Microbiology

Volumn 7, Issue 1, 2012, Pages 1-4

  Kondratowicz, Andrew S ^a   Maury, Wendy J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

antiviral; ebolavirus; filovirus; marburgvirus; vaccine

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; EBOLA VACCINE; FGI 103; FGI 104; FGI 106; GAMMA INTERFERON; GLYCOPROTEIN; MESSENGER RNA; MUCIN 1; NUCLEOPROTEIN; PROTEIN C; RECOMBINANT PROTEIN; RNA DIRECTED RNA POLYMERASE; THROMBOPLASTIN; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS RNA; VIRUS VECTOR;

BLOOD CLOTTING; DENDRITIC CELL; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FILOVIRIDAE; GENE REPLICATION; GENETIC TRANSCRIPTION; GENOME; HUMAN; IMMUNE RESPONSE; LIQUID; MALARIA; MARBURG VIRUS; MORTALITY; MULTIPLE ORGAN FAILURE; NEMATODE; NIPAH VIRUS; NONHUMAN; PALLIATIVE THERAPY; PARAINFLUENZA VIRUS 3; PRIMATE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SEPSIS; SIGNAL TRANSDUCTION; VENEZUELAN EQUINE ENCEPHALITIS; VESICULAR STOMATITIS VIRUS; VIRUS LOAD;

ANIMALS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EBOLA VIRUS; MARBURGVIRUS;

EID: 84555202690     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.110     Document Type: Review

References (20)

1. Hartman AL, Towner JS, Nichol ST. Ebola and marburg hemorrhagic fever. Clin. Lab. Med. 30, 161-177 (2010).
2. Feldmann H, Geisbert T W. Ebola haemorrhagic fever. Lancet 377, 849-862 (2011).
3. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective Immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7, 393-400 (2009).
4. Gupta M, Goldsmith CS, Metcalfe MG, Spiropoulou CF, Rollin PE. Reduced virus replication, proinfammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo ebolavirus relative to Zaire ebolavirus. Virology 402, 203-208 (2010).
5. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4(10), E837 (2010).
6. Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Recent advances in Ebolavirus vaccine development. Hum. Vaccin. 6, 439-449 (2010).
7. de Wit E, Feldmann H, Munster VJ. Tackling ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Med. 3, 5 (2011).
8. Leung DW, Prins KC, Borek DM et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17, 165-172 (2010).
9. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev. Med. Virol. 20, 344-357 (2010).
10. Warren TK, Warfeld KL, Wells J et al. Advanced antisense therapies for postexposure protection against lethal flovirus infections. Nat. Med. 16, 991-994 (2010).
11. Kondratowicz AS, Lennemann NJ, Sinn PL et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl Acad. Sci. USA 108, 8426-8431 (2011).
12. Basu A, Li B, Mills DM et al. Identifcation of a small-molecule entry inhibitor for floviruses. J. Virol. 85, 3106-3119 (2011).
13. Yermolina MV, Wang J, Caffrey M, Rong LL, Wardrop DJ. Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of floviral entry. J. Med. Chem. 54(3), 765-781 (2011).
14. Miller EH, Harrison JS, Radoshitzky SR et al. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J. Biol. Chem. 286, 15854-15861 (2011).
15. Wolf MC, Freiberg AN, Zhang T et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA 107, 3157-3162 (2010).
16. Carette JE, Raaben M, Wong AC et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
17. Cote M, Misasi J, Ren T et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344-348 (2011).
18. Kinch MS, Yunus AS, Lear C et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am. J. Transl. Res. 1, 87-98 (2009).
19. Aman MJ, Kinch MS, Warfeld K et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 83, 245-251 (2009).
20. Warren TK, Warfeld KL, Wells J et al. Antiviral activity of a small-molecule inhibitor of flovirus infection. Antimicrob. Agents Chemother. 54, 2152-2159 (2010).